Intersouth Partners

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

EDJX is focused on creating a decentralized edge computing platform aimed at addressing the growing demand for efficient data processing. This platform offers ultra-low latency capabilities and serverless computing, enabling developers to build secure Internet of Things (IoT) and machine-to-machine (M2M) applications. By directing serverless requests to the nearest devices, EDJX minimizes latency and bandwidth constraints, allowing for seamless execution of applications in isolated environments. The company also provides essential services such as content delivery networks, object storage, and DNS, enhancing the overall functionality of its edge cloud solutions.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Azalea Health is a prominent provider of cloud-based healthcare solutions and services tailored for health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated technologies, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), telehealth services, and professional consulting. Azalea Health's solutions are designed to enhance patient engagement and streamline operational workflows for practices of various sizes and specialties. Additionally, the platform equips clients with tools to meet regulatory requirements such as Meaningful Use and ICD-10, ultimately aiming to optimize both operational efficiency and revenue generation.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

LocationSmart is a leading provider of cloud-based location services, headquartered in Carlsbad, California. Founded in 1995, the company specializes in geolocation solutions for various industries, including gaming, IoT asset management, and transportation. Its services are designed to ensure geolocation compliance in sectors such as Daily Fantasy Sports, online poker, and online casinos. LocationSmart operates a comprehensive location platform that supports a wide range of connected devices and networks, enabling businesses to enhance customer engagement, operational efficiency, and security through real-time location data. The company's offerings include location determination based on IP addresses, cell or Wi-Fi IDs, and mobile app SDKs, along with messaging services for geo-enabled communication. With a focus on privacy and consent management, LocationSmart aims to protect user data while providing companies with actionable insights to optimize their operations. The company serves a diverse clientele, from startups to Fortune 500 companies, and has established itself as a significant player in the global location services market.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, specifically targeting complications such as diabetic nephropathy. Founded in 2005 and based in North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to respond to hyperglycemia. This innovative treatment aims to bind to a specific molecular target within the αVβ3 receptor, potentially offering patients a means to mitigate the serious complications associated with diabetes. Vascular Pharmaceuticals operates at the intersection of biotechnology, medicine, and healthcare, contributing to the ongoing efforts to improve outcomes for those affected by diabetes.

Azalea Health is a prominent provider of cloud-based healthcare solutions and services tailored for health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated technologies, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), telehealth services, and professional consulting. Azalea Health's solutions are designed to enhance patient engagement and streamline operational workflows for practices of various sizes and specialties. Additionally, the platform equips clients with tools to meet regulatory requirements such as Meaningful Use and ICD-10, ultimately aiming to optimize both operational efficiency and revenue generation.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Learn to play the music you love in the Zenph Online Education Network (ZOEN). We deliver the perfect match between teachers and students through live online music lessons. Whether you’re looking to learn your favorite song, seeking advice on perfecting your technique or searching for the right music teacher for your kids, taking a live online music lesson from one of the ZOEN’s experienced, nationally renowned music teachers is just a matter of a few clicks! The ZOEN is brought to you by Zenph, Inc. – our award winning Re-Performance® technology was named one of the “Best Ideas of the Year” by The New York Times Magazine and has earned us accolades from music lovers and critics the world over, including multiple GRAMMY® nominations. Based in North Carolina’s Research Triangle Park, we are a venture-backed technology company led by a team of music and software professionals with expertise in music education, consumer software, social gaming and entertainment.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.

ABT Molecular Imaging is a medical imaging company that specializes in the design, manufacture, and marketing of biomarker generator systems for positron emission tomography (PET). Headquartered in Knoxville, Tennessee, the company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs on demand, facilitating immediate use at the point of care. The generator incorporates features such as quality control tests and detailed dose records to ensure reliability and compliance. Founded by Ron and Lynda Nutt in 2006, ABT aims to enhance the global expansion of PET imaging by providing innovative solutions for pharmaceutical companies. Its products are distributed through a comprehensive network of sales and service partners.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, specifically targeting complications such as diabetic nephropathy. Founded in 2005 and based in North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to respond to hyperglycemia. This innovative treatment aims to bind to a specific molecular target within the αVβ3 receptor, potentially offering patients a means to mitigate the serious complications associated with diabetes. Vascular Pharmaceuticals operates at the intersection of biotechnology, medicine, and healthcare, contributing to the ongoing efforts to improve outcomes for those affected by diabetes.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.

Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

simplifyMD, based in Alpharetta, Georgia, is an electronic health records (EHR) provider established in 2006. The company offers a web-based platform designed for physician practices, featuring ONC-ATCB certified technologies that enhance the management of electronic medical records. simplifyMD's solutions include medical-grade document management and Patient Health Record technologies, utilizing barcode and optical character recognition to streamline the handling of documents. This innovative approach allows healthcare offices to automatically index and manage their records, reducing the need for manual sorting of scans and improving overall efficiency in medical record management.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet edge and aggregation services tailored for carrier-class service providers. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional development offices in Westford, Massachusetts, and Bangalore, India, the company offers a diverse range of products. These include the Overture Orchestrator for cost-effective service delivery, Overture Analytics for actionable intelligence, and various Ethernet access devices that facilitate the transition from traditional TDM infrastructure to modern Ethernet networks. Key offerings also encompass the Overture 65vSE, a carrier-class server, and platforms like the Overture 6500 for performance-assured services across multiple transport mediums. By integrating packet-switched and circuit-switched technologies, Overture Networks delivers adaptable and cost-efficient solutions that cater to various service provider requirements.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.

ABT Molecular Imaging is a medical imaging company that specializes in the design, manufacture, and marketing of biomarker generator systems for positron emission tomography (PET). Headquartered in Knoxville, Tennessee, the company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs on demand, facilitating immediate use at the point of care. The generator incorporates features such as quality control tests and detailed dose records to ensure reliability and compliance. Founded by Ron and Lynda Nutt in 2006, ABT aims to enhance the global expansion of PET imaging by providing innovative solutions for pharmaceutical companies. Its products are distributed through a comprehensive network of sales and service partners.

MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Acquired by Steinway & Sons Inc., January 2015. Zenph Sound Innovations is a developer of musical analysis technology focused on software services and apps related to music. Zenph Sound Innovations offers technology that converts audio recordings into datasets, enabling a virtual artist play re-performances, precisely replicating a musician’s playing in an original recording.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.

Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Bright View Technologies, Inc. specializes in the development of microstructure-based optical films tailored for the global display industry. The company employs patented technologies to create advanced optical film products that enhance performance in various display types, including Plasma, LCD, Rear Projection, Front Projection, and OLED. Additionally, Bright View's engineered optics devices are applicable in other areas such as lighting and LiDAR, allowing clients to achieve improved brightness, efficiency, and uniformity in their display applications. Through its innovative approach, Bright View Technologies aims to meet the evolving needs of the display market.

Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Clarabridge is a Customer Experience Management platform that assists businesses in enhancing their customer interactions. By leveraging advanced text analytics and natural language processing technology, the platform transforms various forms of customer feedback—such as contact center calls, comments, and reviews—into actionable insights. This enables organizations to understand customer sentiments better and make informed decisions that drive improvements in customer experience. Since its establishment, Clarabridge has served numerous leading brands, helping them to grow sales, ensure compliance, and increase operational efficiency through a deep understanding of customer feedback.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Athenix is a prominent player in the field of agricultural and industrial biotechnology, specializing in the development of products, technologies, and processes tailored for agricultural and chemical applications. The company is dedicated to discovering new genes and transforming them into practical solutions that address specific customer requirements. Athenix focuses on creating plants, microbes, enzymes, and processes aimed at enhancing insect and nematode resistance, as well as herbicide tolerance. Additionally, its research extends to the identification of genes and proteins utilized in the chemical and animal feed industries, reinforcing its commitment to innovation in biotechnology.

siXis is a semiconductor company that provides silicon circuit board technology.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.

Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.

Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.

Mixx is a social news platform that allows users to discover and share news based on their interests and location. Founded by Chris McGill, former General Manager of Yahoo News, Mixx combines elements of social networking with news aggregation, creating a personalized experience for each user. Users can bookmark stories, photos, and videos, as well as submit and vote on content, fostering a community-driven environment. The platform also provides a customized homepage featuring relevant news items, popular stories, and categorized sections such as business, sports, and health. Additionally, users can join topical groups to refine the news they receive. Mixx aims to support niche publishers by promoting less mainstream topics that may not gain traction on larger platforms. By partnering with publishing entities, Mixx facilitates traffic exchange, benefiting both users and content creators.

Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.

NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet edge and aggregation services tailored for carrier-class service providers. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional development offices in Westford, Massachusetts, and Bangalore, India, the company offers a diverse range of products. These include the Overture Orchestrator for cost-effective service delivery, Overture Analytics for actionable intelligence, and various Ethernet access devices that facilitate the transition from traditional TDM infrastructure to modern Ethernet networks. Key offerings also encompass the Overture 65vSE, a carrier-class server, and platforms like the Overture 6500 for performance-assured services across multiple transport mediums. By integrating packet-switched and circuit-switched technologies, Overture Networks delivers adaptable and cost-efficient solutions that cater to various service provider requirements.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.

Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.

Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.

Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.

Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.

Mixx is a social news platform that allows users to discover and share news based on their interests and location. Founded by Chris McGill, former General Manager of Yahoo News, Mixx combines elements of social networking with news aggregation, creating a personalized experience for each user. Users can bookmark stories, photos, and videos, as well as submit and vote on content, fostering a community-driven environment. The platform also provides a customized homepage featuring relevant news items, popular stories, and categorized sections such as business, sports, and health. Additionally, users can join topical groups to refine the news they receive. Mixx aims to support niche publishers by promoting less mainstream topics that may not gain traction on larger platforms. By partnering with publishing entities, Mixx facilitates traffic exchange, benefiting both users and content creators.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

FlatBurger, Inc. provides business infrastructure for supporting software developers working in hybrid software environments. It offers business infrastructure to complement the development tools employed in the Microsoft visual studio environment. The company focuses on serving the DotNetNuke community of software developers. FlatBurger, Inc. is based in Loudonville, New York with additional offices in northern Virginia and Troy.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.

Clarabridge is a Customer Experience Management platform that assists businesses in enhancing their customer interactions. By leveraging advanced text analytics and natural language processing technology, the platform transforms various forms of customer feedback—such as contact center calls, comments, and reviews—into actionable insights. This enables organizations to understand customer sentiments better and make informed decisions that drive improvements in customer experience. Since its establishment, Clarabridge has served numerous leading brands, helping them to grow sales, ensure compliance, and increase operational efficiency through a deep understanding of customer feedback.

Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.

Jacket Micro Devices specializes in providing solutions for wireless modules, focusing on technology that minimizes the size and cost of radio frequency components in wireless devices. Founded in 2004 and located in Atlanta, Georgia, the company offers a range of products including modules, design services, and substrates for integrated wireless systems. Additionally, it develops advanced technologies such as multi-layer organic (MLO) and low temperature laminated organic (LTLO) for system-in-package (SiP) designs, enhancing the efficiency and performance of wireless communications.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.

Covega Corporation specializes in the development and production of optoelectronic components and subsystems, utilizing proprietary technologies in Indium Phosphide and Lithium Niobate. The company offers a range of high-performance optical devices and modules, including superluminescent diodes, semiconductor optical amplifiers, Fabry Perot lasers, gain chips, and lithium niobate modulators. With a significant portion of its revenue derived from the defense, medical, industrial, and instrumentation sectors, Covega has expanded beyond its initial focus on telecom, datacom, and CATV industries. The firm provides vertically integrated capabilities and foundry services, catering to a diverse clientele with tailored products and solutions designed to meet various operational needs.